POTP Point Therapeutics (MM)

Point Therapeutics, Inc. (NASDAQ:POTP) presented preclinical data on its lead product candidate talabostat, demonstrating anti-tumor activity when combined with either pemetrexed or erlotinib in a non-small lung cancer (NSCLC) xenograft model in immunodeficient mice at a poster session today at the AACR-EORTC-NCI International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, PA. As a single agent, talabostat caused a 35% greater reduction in tumor size than pemetrexed alone. Administration of 500 mg/kg of pemetrexed alone did not significantly impact tumor growth. When talabostat and pemetrexed were combined, the anti-tumor effect was significantly greater (p